Related Experiment Video

Updated: Jul 14, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with

Chih-Sheng Chu1, Kun-Tai Lee, Shuo-Tsan Lee

  • 1Division of Cardiology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.

The Kaohsiung Journal of Medical Sciences
|May 26, 2007
PubMed

Insights

Statins may reduce arrhythmia risk, but this study found atorvastatin did not significantly alter key ECG markers in hypercholesterolemia patients. Further research is needed to understand statins' antiarrhythmia effects in low-risk individuals.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Electrocardiography

Background:

  • Statins are known to reduce cardiovascular events.
  • Emerging evidence suggests statins may have antiarrhythmic properties, particularly in patients with structural heart disease.
  • The direct impact of statins on specific electrocardiographic (ECG) markers of arrhythmia risk in patients without structural heart disease is less understood.

Purpose of the Study:

  • To investigate the direct effects of atorvastatin on ECG-based arrhythmia risk stratification parameters.
  • To assess changes in ventricular late potentials, QT dispersion, and T wave repolarization parameters.
  • To evaluate these effects in hypercholesterolemia patients without structural heart disease.

Main Methods:

  • Prospective study involving 82 hypercholesterolemia patients treated with atorvastatin 10 mg/day for 3 months.
  • Surface 12-lead ECG and signal-averaged ECG (SAECG) recorded pre- and post-treatment.
  • Analysis of SAECG parameters, QT dispersion, Bazett-corrected QT (QTc) dispersion, T wave peak-to-end interval (Tpe), and Tpe/QT ratio.
  • 24-hour ambulatory ECGs performed in a subset of patients.

Main Results:

  • Atorvastatin significantly reduced total and LDL cholesterol levels (p < 0.001).
  • No significant changes were observed in SAECG parameters, late potentials, QT dispersion, QTc dispersion, Tpe, or Tpe/QT ratio post-treatment.
  • A flattening of circadian QTc dispersion variation was noted on 24-hour ambulatory ECGs.

Conclusions:

  • Atorvastatin therapy did not significantly alter the analyzed noninvasive ECG risk stratification parameters in low-risk hypercholesterolemia patients.
  • The direct antiarrhythmic effects of atorvastatin may not be readily detectable through these specific ECG markers in this population.
  • Further investigation is required to elucidate the antiarrhythmic mechanisms of statins in patients without structural heart disease.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...